Tesamorelin Dosing Protocol: Injection, Pen Vial, Nasal Spray & Reconstitution (2026)

Tesamorelin Quick Start

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). It stimulates the pituitary to release growth hormone (GH) in a natural, pulsatile pattern, raising IGF-1. It is studied for reducing excess visceral abdominal fat in HIV-associated lipodystrophy, and more broadly in GH-axis and body-composition research.

Quick reference Clinical-trial data

Class

GHRH analog

Formats

Vial · Pen vial · Nasal spray

Action

Pulsatile GH release → IGF-1

Schedule shape

Once daily

Vial size

10 mg

This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.

Tesamorelin Dosing Protocols

The injectable (subcutaneous), pen-vial and nasal-spray formats are documented as separate protocols. The reference dose comes from the approved indication (2 mg once daily, subcutaneous). This is shown as research context, not a personal dosing recommendation.

Injection — Subcutaneous

Reconstituted 10 mg vial, U-100 insulin syringe.

Band	Per dose	Frequency
Reference	2 mg	Once daily

10 mg + 2 mL BAC → 5 mg/mL · 2 mg = 0.4 mL = 40 units

Nasal Spray

Pre-mixed nasal spray, ready to use.

Band	Per dose	# of sprays	Frequency
Reference	2 mg	10 sprays	Once daily

Each 0.1 mL spray delivers 0.2 mg (200 mcg)

Pen Vial — Pre-Reconstituted 3 mL

Supplied already reconstituted to 3 mL — no mixing step. Doses are given in units, the scale a reusable pen dials in (300 units per vial). Pens step in whole or half units depending on the model — round any fractional figure to the nearest increment your device supports.

Band	Per dose (units)	Delivers	Frequency
Reference	60 units	2 mg	Once daily

10 mg in 3 mL → 33.3 mcg per unit · 300 units per pen · ~5 doses at 2 mg

At the 2 mg reference dose one pen covers about five doses. The lyophilized vial is the longer-running format for a daily milligram-range schedule.

The approved Tesamorelin dose is 2 mg/day — a milligram-range dose. The spray uses a concentrated 5 mL fill (0.2 mg/spray), so 2 mg ≈ 10 sprays; the injection is the more compact route. GH secretagogues are commonly researched with bedtime, empty-stomach timing.

Tesamorelin Reconstitution Guide

Tesamorelin ships as a lyophilized powder. The BAC water volume sets the concentration and draw volume for the injectable vial. Nasal sprays and pen vials both ship ready to use — the pen at a fixed 3 mL fill, so no water is added to it at all.

Injection

BAC	Conc.	2 mg
2 mL	5 mg/mL	0.4 mL · 40 u
1 mL	10 mg/mL	0.2 mL · 20 u

Units are U-100 syringe units.

Pen Vial — 3 mL

Format	Conc.	2 mg
3 mL (as supplied)	3.33 mg/mL	0.6 mL · 60 u

Ships pre-reconstituted; no BAC water is added. 33.3 mcg per unit on a U-100 scale.

Reconstitution steps

Inspect the vial. Confirm label and intact powder.
Wipe the stoppers. Alcohol swab on both vials.
Draw BAC water. 2 mL into the injectable vial.
Inject down the wall. Release water slowly down the inside wall, not onto the powder.
Swirl, do not shake. Roll gently until clear.
Refrigerate. Store at 2–8 °C; do not freeze.

How to use the pen vial

Inspect the vial. Confirm the label and strength. The solution should be clear and colorless.
Never add water. A pen vial ships at its final 3 mL volume. Adding bacteriostatic water would dilute it and invalidate every unit figure on this page.
Load the vial into the pen. Unscrew the pen's cartridge holder, seat the vial, and screw the holder back on until firm.
Attach a fresh needle tip. Screw a new disposable pen needle onto the holder, then pull off the outer and inner caps. Use a new tip for every dose.
Prime the pen. Dial 2 units, hold the pen needle-up, tap the holder so any air rises to the top, and press the button until a drop appears at the tip. Repeat until it does.
Spin to the dose. Turn the dial to the unit figure from the table above. If you overshoot, spin back — never press the button to correct an overshoot.
Inject and hold. Press the button all the way down, then keep the needle in place for about ten seconds before withdrawing so the full dose is delivered.
Remove and dispose of the needle. Unscrew the tip into a sharps container. Never store the pen with a needle attached — it lets solution leak out and air in.
Cap and refrigerate. Store the pen with the vial still seated at 2–8 °C. Do not freeze.

How to use the nasal spray

Prime first use. Pump 2–3 sprays into a tissue until a fine, even mist appears.
Position. Tilt the head slightly forward; insert the tip just inside one nostril, aimed slightly outward toward the ear — not at the septum.
Spray and breathe. Press once while breathing in gently; do not sniff hard, which sends the solution down the throat instead of onto the mucosa.
Alternate nostrils. For multi-spray doses, switch nostrils each spray to spread absorption and limit irritation.
Count per the protocol. Use the sprays-per-dose shown above; if a dose isn't a whole number, round up.
Between uses. Wipe the tip, recap, and refrigerate.

How Tesamorelin Works

Tesamorelin binds GHRH receptors on the pituitary and stimulates the synthesis and pulsatile release of endogenous growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1). Because it works upstream — prompting the body's own GH pulses rather than supplying GH directly — the GH rise follows a more physiologic pattern. In its approved indication it reduces visceral adipose tissue.

GHRH agonism

Stimulates pituitary GH synthesis and release.

Pulsatile GH

Promotes natural GH pulses rather than constant exogenous GH.

Visceral fat

Approved effect: reduction of visceral adipose tissue.

IGF-1 rise

Downstream IGF-1 increases; monitored as a safety/effect marker.

Who Should Avoid Tesamorelin

Active malignancy

Contraindicated; GH/IGF-1 elevation is a concern with active cancer.

Pregnancy

Contraindicated in the approved labeling.

Disrupted pituitary/HPA axis

Pituitary disease or hypophysectomy affects the GHRH response.

Diabetes / glucose issues

GH elevation can raise blood glucose; monitor closely.

Tesamorelin Side Effects & Safety

Injection-site reactions

The most commonly reported effect in trials; rotate sites.

Arthralgia / fluid retention

Joint pain, swelling, and edema are reported, consistent with GH-axis activity.

Glucose effects

GH elevation can worsen insulin resistance; monitor blood sugar.

IGF-1 elevation

Tracked as a safety marker; sustained high IGF-1 warrants dose review.

Timeline & What to Monitor

Timeframe	Commonly tracked	Notes
Week 1–2	Injection-site tolerance, fluid retention	Early GH-axis effects appear here.
Week 4–8	IGF-1, glucose	IGF-1 is the primary biochemical marker; check glucose.
Month 3–6	Visceral fat / body composition	The approved endpoint develops over months.

Clinical Evidence Context

Approval trials

Phase 3 trials supported approval for reducing visceral fat in HIV-associated lipodystrophy.

NAFLD research

Studied for liver-fat reduction in subsequent research.

GH-axis marker

IGF-1 response is well characterized as the pharmacodynamic readout.

Boundary

Use outside the approved indication is off-label/research context.

Storage & Handling

State	Storage	Notes
Lyophilized (powder)	−20 °C long-term; fridge short-term	More stable than reconstituted solution.
Reconstituted (liquid)	2–8 °C	Use within ~3–4 weeks; do not freeze.
Appearance	Clear, colorless	Discard cloudy or particulate solutions.

Mistakes & Troubleshooting

Too many sprays feel impractical. The 2 mg dose is milligram-range; the injection is the compact route. The spray needs ~10 sprays.
Wrong BAC volume. Recalculate concentration; injection assumes 2 mL, spray assumes 5 mL.
Fluid retention / joint pain. Common GH-axis effects; review dose with a clinician if persistent.
Left out overnight. Treat reconstituted solution as compromised and discard.

Tesamorelin vs Other GH Secretagogues

Feature	Tesamorelin	GHRP-class peptides
Class	GHRH analog	Ghrelin-receptor / GHRP
Action	Stimulates pituitary GHRH receptor	Acts via ghrelin receptor to pulse GH

Blood Tests & Monitoring

Marker	Why	Timing
IGF-1	Primary pharmacodynamic and safety marker for GH-axis activity	Baseline + periodic
Fasting glucose / HbA1c	GH elevation can affect glucose handling	Baseline + periodic
CMP	General safety screen	Baseline

Frequently Asked Questions

What is Tesamorelin?

A stabilized GHRH analog that stimulates natural pulsatile GH release. It is studied for reducing visceral fat in HIV-associated lipodystrophy and more broadly in GH-axis research.

How is the injection dosed vs the nasal spray?

Separate protocols. The reference dose is 2 mg once daily subcutaneous. Because 2 mg is milligram-range, the spray uses a concentrated 5 mL fill (0.2 mg/spray), so 2 mg ≈ 10 sprays — the injection is the more compact route.

How is Tesamorelin reconstituted?

For injection, 10 mg in 2 mL BAC water gives 5 mg/mL, so 2 mg = 0.4 mL = 40 units. The spray ships pre-mixed and delivers 0.2 mg per spray.

What should be monitored?

IGF-1 is the primary marker, along with glucose. Discuss baseline and periodic labs with a clinician.

What is the pen-vial format?

A 10 mg pen vial supplied already reconstituted to 3 mL — 300 units at 33.3 mcg per unit. The 2 mg reference dose is 60 units (0.6 mL), so one pen holds about five doses.

Is this page medical advice?

No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.

Tesamorelin Formats & Sourcing

The protocols above are written against the formats Tesamorelin is actually supplied in. Batch-specific Certificates of Analysis are issued per lot; always verify the strength on the label against the figures used here before calculating anything.

Format	Supplied as
Vial	10 mg lyophilized powder
Pen vial	Pre-reconstituted, 3 mL
Nasal spray	Pre-mixed, 0.2 mg per spray
Nasal spray — 5-pack	Bulk: five nasal spray units
Vial — 5-pack	Bulk: five vial units

5-packs are available for the nasal spray and vial formats. Strengths and formats are listed as sold; confirm against the product page and the batch COA.

Reference material for this protocol, with batch COA:

View Tesamorelin on Spyro Peptides →

Purity 99+% HPLC Batch COA available Research use only

References

Falutz J, et al. Tesamorelin for reduction of visceral adipose tissue (Phase 3). N Engl J Med / J Clin Endocrinol Metab (2010).
Stanley TL, et al. Tesamorelin and liver fat (NAFLD). Lancet HIV / JAMA (2019).
World Anti-Doping Agency. Prohibited List 2025 (GHRH analogs).